ArticleCureus2025
A Patient With Brain Metastasis From a Gastric Tumor.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases secondary to gastric carcinoma are exceedingly rare and are associated with a poor prognosis. Their clinical presentation may mimic common neurological conditions, making early diagnosis and timely management challenging. We report the case of a 68-year-old male with a history of diabetes and hypertension who presented with sudden left-sided hemiparesis and urinary incontinence. Brain CT revealed a right frontal lesion with surrounding edema. He underwent craniotomy with tumor resection, and histopathological analysis confirmed a poorly differentiated gastric adenocarcinoma with human epidermal growth factor receptor 2 (HER2) overexpression (3+), consistent with brain metastasis of gastric origin. Systemic treatment with oxaliplatin and capecitabine was initiated, and anti-HER2-targeted therapy was considered. This report highlights the importance of maintaining a high index of suspicion for brain metastasis in patients with space-occupying lesions, even in the absence of a prior cancer diagnosis. The combination of neuroimaging, surgery, immunohistochemistry, and tailored oncologic treatment enabled timely intervention. The report underscores the value of interdisciplinary management and the clinical utility of biomarkers such as HER2 in guiding therapy in rare clinical scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.